Adcetris Could Be Curative in Some Patients with Refractory Hodgkin's

A phase II study of Adcetris in a traditionally difficult-to-treat patient population shows survival and cure potential.

According to the presentation made at the ASH meeting in December of 2013, about half of the patients in the trial diagnosed with relapsed or refractory Hodgkin’s lymphoma and treated with brentuximab vedotin in the study were alive at three years.

Ajay K. Gopal, MD, associate professor at the University of Washington, a member of Fred Hutchinson Cancer Research Center and director of clinical research in hematologic malignancies at the Seattle Cancer Care Alliance, told HemOncToday, "The most interesting finding is that about 10 percent of patients on this trial have been off therapy and are enjoying long-term remissions."

Studying the curative potential of Adcetris

The trial (median patient age, 31) tested Adcetris in 102 patients following an autologous stem cell transplantation (ASCT). Patients received a median of nine cycles of Adcetris.

The researcher gave the three-year survival rate as 54 percent, with 51 of 102 patients still alive after a median of 32.7 months from their first dose of Adcetris.

Furthermore, a full 18 patients are said to still be in remission by the standards of the investigators (that number dips to 14 per central independent review). Five of these patients received consolidative allogeneic stem cell transplantation, and nine received no additional treatment after Adcetris.

Those in remission tended to be younger in age and underwent more treatment cycles than those not in remission.

Regarding those patients and their remissions, Gopal said that it "raises the question that this agent may have curative potential in a subset of patients and sets the stage for formally evaluating this agent as part of initial therapy."

Source: HemOncToday

More Articles

More Articles

Mantle cell lymphoma (MCL) is a rare type of B-Cell lymphoma. It presents itself in the mantle zone of lymph nodes...

Large Cell Lymphoma (LCL) is typically an aggressive (fast growing) cancer of either the B cell or T cell type. They are one of the most common...

Indolent Lymphoma, or Indolent Non-Hodgkin’s Lymphomas (NHLs), are slow growing, low-grade cancers (as opposed to ...

A lymphoma prognosis varies greatly depending on the type of lymphoma. There are more than 35 types of lymphoma, including 5 types of...

Lymphomas are classified based on the type of cells involved. Non-Hodgkin’s lymphomas are marked by mutations of...

Hodgkin's Lymphoma (Disease) has a colorful history: It was not the first cancer discovered but it was one of the first in which treatments were...

There are two types of cancer: benign and malignant. Benign cancers are the kind that don't spread and don't threaten one's life. Malignant...

Cancer bracelets are undeniably popular, and if purchased through reliable sources such as major charities, they help contribute to the fight...

Hodgkin's Disease—also referred to as Hodgkin's Lymphoma, these are the exact same diseases, just...

Lymphoma is a cancer of the b- and t-cell lymphocytes, part of the immune system. They account for the most frequent head and neck malignancies....

Lymphoma is a cancer of the lymphatic system, causing B-cell or...

Lymphoma is a cancer affecting the white blood cells (lymphocytes) of the body's immune system. The cells begin to grow abnormally and much faster...

As a kind of cancer, lymphoma attacks the lymphocytes and lymph nodes that are part of the immune system. Head and neck lymphoma results when...

Some cancers have clear environmental causes. Oral cancer is strongly tied to the use of chewing tobacco, and lung cancer is well-known to be much...

The Follicular Lymphoma International Prognostic Index, or FLIPI, is a standardized guide to help oncological diagnosticians accurately calculate...